Oriola

0.93 EUR

-0.32 %

7,748 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.32 %
-1.38 %
-13.06 %
-18.96 %
-16.49 %
-15.88 %
-32.95 %
-48.96 %
-49.33 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
172.72M EUR
Turnover
93.88K EUR
P/E (adj.) (26e)
16.97
EV/EBIT (adj.) (26e)
1.73
P/B (26e)
1.75
EV/S (26e)
0.19
Dividend yield-% (26e)
3.22 %
Coverage
Recommendation
Accumulate
Target price
1.10 EUR
Updated
30.04.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 30.04.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Third party research

Oriola: Solid mid-term potential - Evli

With the financial targets announced earlier along with major investments known, Oriola’s CMD was limited in terms of significant new news, which we see as a positive given earlier concerns. More clarity was however provided on the roadmap to achieving...

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Soft start but expecting improvement - Evli

Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year.

Oriola
Third party research

Oriola: Softer profitability, good growth - Evli

Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, with the latter up 8.1% y/y. The adj. EBITDA of EUR 7.7m fell well short of our EUR 8.5m expectations, with profitability in the Services-segment declining...

Oriola

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.